# GlaxoSmithKline clinical trials: 3,652 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 3,652 trials with GlaxoSmithKline as lead sponsor, 116 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by GlaxoSmithKline: 3,652 rows for $116.52, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/glaxosmithkline

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 3,652
- Recruiting or not yet: 116
- Read on: November 19, 2026

## Trials

The 25 newest of 3,652, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| November 4, 2026 | NCT07915791 | A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe... | GlaxoSmithKline | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915791) |
| November 2, 2026 | NCT07908459 | B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants | GlaxoSmithKline | Phase 4 | Not yet recruiting | Hepatitis B | 303 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908459) |
| October 29, 2026 | NCT07905157 | A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants | GlaxoSmithKline | Phase 1 | Not yet recruiting | Hepatitis B | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905157) |
| October 13, 2026 | NCT07872046 | A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults \>=50 Years of Age With Established... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Cardiovascular Disease | 16,390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872046) |
| October 9, 2026 | NCT07867171 | A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib | GlaxoSmithKline | Phase 1 | Not yet recruiting | Healthy Participants, Gastrointestinal Neoplasms | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867171) |
| October 7, 2026 | NCT07862114 | A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants | GlaxoSmithKline | Phase 1 | Not yet recruiting | Healthy Participants, Gastrointestinal Neoplasms | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862114) |
| October 6, 2026 | NCT07860710 | J-LINX: Japan LINerixibat eXtension Study | GlaxoSmithKline | Phase 3 | Not yet recruiting | Pruritus | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860710) |
| October 6, 2026 | NCT07860450 | Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Endometrial Carcinoma, Neoplasms, Endometrial | 378 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860450) |
| October 6, 2026 | NCT07859735 | A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib | GlaxoSmithKline | Phase 1 | Not yet recruiting | Healthy Participants, Gastrointestinal Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859735) |
| October 1, 2026 | NCT07851246 | A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07851246) |
| September 30, 2026 | NCT07850141 | Prospective Registry of Exposure to Gepotidacin (PREG) | GlaxoSmithKline | Observational | Recruiting | Sexually Transmitted Diseases | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850141) |
| September 28, 2026 | NCT07843641 | A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) | GlaxoSmithKline | Phase 2 | Not yet recruiting | Gastrointestinal Neoplasms | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843641) |
| September 17, 2026 | NCT07825701 | Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations | GlaxoSmithKline | Not applicable | Available | Gastrointestinal Neoplasms | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825701) |
| September 4, 2026 | NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 54,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805707) |
| September 3, 2026 | NCT07802704 | A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) \[EMBOLD Prostate-302\] | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Prostate | 684 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802704) |
| August 27, 2026 | NCT07791043 | A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver... | GlaxoSmithKline | Phase 2 | Recruiting | Liver Diseases, Alcoholic | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791043) |
| August 27, 2026 | NCT07789899 | A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants | GlaxoSmithKline | Phase 1 | Recruiting | Pulmonary Disease, Chronic Obstructive | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789899) |
| August 25, 2026 | NCT07784894 | A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With... | GlaxoSmithKline | Phase 1 | Recruiting | Tuberculosis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784894) |
| August 24, 2026 | NCT07782996 | A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST... | GlaxoSmithKline | Phase 3 | Recruiting | Asthma | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782996) |
| August 24, 2026 | NCT07782970 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps... | GlaxoSmithKline | Phase 3 | Recruiting | Nasal Polyps | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782970) |
| August 24, 2026 | NCT07782957 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis... | GlaxoSmithKline | Phase 3 | Recruiting | Nasal Polyps | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782957) |
| August 21, 2026 | NCT07780669 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780669) |
| August 21, 2026 | NCT07780656 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780656) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1,044 |
| Phase 1/2 | 57 |
| Phase 2 | 803 |
| Phase 2/3 | 5 |
| Phase 3 | 900 |
| Phase 4 | 326 |
| Not applicable | 120 |
| Observational | 397 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 3,116 |
| Terminated | 241 |
| Withdrawn | 110 |
| Recruiting | 93 |
| Active not recruiting | 56 |
| Not yet recruiting | 23 |
| No longer available | 5 |
| Unknown | 4 |
| Available | 2 |
| Approved for marketing | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 276 |
| Asthma | 261 |
| Influenza, Human | 184 |
| Hepatitis B | 142 |
| Neoplasms | 136 |
| Diabetes Mellitus, Type 2 | 129 |
| Tetanus | 102 |
| Diphtheria | 97 |
| Haemophilus Infections | 82 |
| Papillomavirus Infections | 71 |
| Meningococcal Infections | 71 |
| Streptococcal Infections | 64 |
| Rotavirus Infections | 61 |
| Breast Neoplasms | 55 |
| Epilepsy | 54 |
| Poliomyelitis | 44 |
| Carcinoma, Non-Small-Cell Lung | 43 |
| Prostatic Hyperplasia | 43 |
| Herpes Zoster | 43 |
| Malaria | 41 |
| Infections | 40 |
| Arthritis, Rheumatoid | 40 |
| Multiple Myeloma | 40 |
| Respiratory Syncytial Virus Infections | 39 |
| Depressive Disorder | 39 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Family practice clinics in the United States](https://specstream.ai/data/businesses/family-practice-clinics/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Italian restaurants in the United States](https://specstream.ai/data/businesses/italian-restaurants/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Pediatric orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-orthopedic-surgery-practices/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
